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This is one of a series of occasional articles that highlight areas of
practice where management lacks convincing supporting evidence. The
series adviser is David Tovey, editor in chief, theCochrane Library. This
paper is based on a research priority identified and commissioned by
the National Institute for Health Research’s Health Technology
Assessment programme on an important clinical uncertainty. To suggest
a topic for this series, please email us at uncertainties@bmj.com.
Depression typically runs a relapsing and recurrent course.1
Without ongoing treatment people with recurrent depression
have a very high risk of repeated depressive relapses throughout
their life, even after successful acute treatment. Major inroads
into the substantial health burden attributable to depression
could be offset through interventions that prevent depressive
relapse among people at high risk of recurrent episodes.2 If the
factors that make people vulnerable to depressive relapse can
be attenuated, the relapsing course of depression could
potentially be broken. Currently, most depression is treated in
primary care, and maintenance antidepressants are the mainstay
approach to preventing relapse.3 The UK’s National Institute
for Health and Clinical Excellence (NICE) recommends that to
stay well, people with a history of recurrent depression should
continue taking antidepressants for at least two years. However,
many patients experience side effects, and some express a
preference for psychosocial interventions, which provide long
term protection against relapse.4 Mindfulness based cognitive
therapy (MBCT)5was developed as a psychosocial intervention
for teaching people with a history of depression the skills to
stay well in the long term (see box for a description of MBCT).
A recent systematic review andmeta-analysis of six randomised
controlled trials (n=593) suggests that MBCT significantly
reduces the rates of depressive relapse compared with usual
care or placebo, corresponding to a relative risk reduction of
34% (risk ratio 0.66, 95% confidence interval 0.53 to 0.82).6
However, despite the emerging evidence base6 and widespread
clinical enthusiasm for MBCT,7 several uncertainties remain.
What is the evidence of the uncertainty?
Firstly, it is not clear how MBCT compares with other
approaches to preventing depressive relapse—most notably,
maintenance antidepressants. Evidence from two of the six
randomised controlled trials included in systematic review
mentioned above suggests thatMBCTwas at least as efficacious
as maintenance antidepressants in preventing relapse (risk ratio
0.80, 95% confidence interval 0.60 to 1.08),6 but the sample
sizes were small and the confidence intervals were wide. Even
though antidepressants are the first line approach to preventing
depressive relapse, no trials have yet evaluated whether the
combination of antidepressants and MBCT provides added
benefit over either treatment alone. There are also no head to
head trials comparing MBCT with other psychosocial
approaches known to help people stay well in the long term
(such as cognitive behavioural therapy and interpersonal
therapy).
Secondly, although the six randomised controlled trials have
not yet reported adverse effects, neither have studies explicitly
explored in any depth MBCT’s acceptability in a broad range
of populations. The earliest two trials of MBCT provided
evidence through retrospective analyses suggesting thatMBCT
may be effective only for people who had had three or more
episodes of depression.6 As a result, subsequent trials have
restricted their sample to patients with three or more previous
episodes. Future research is needed to establish how acceptable
MBCT is to a broad range of patients
Thirdly, even though it is nearly 10 years since NICE first
recommended MBCT and even though the 2009 NICE update
identified the therapy as a key priority for implementation, there
is a substantial gap between the efficacy research and
implementation in routine practice settings. A recent survey
suggests that only a small number of mental health services in
the UK have systematically built MBCT into their depression
care pathways.8
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Description of mindfulness based cognitive therapy
Mindfulness based cognitive therapy (www.bemindful.co.uk/mbct/about) is a psychosocial, group based, relapse prevention programme for
people with a history of depression who wish to learn long term skills for staying well. It combines systematic mindfulness training—meditation
exercises targeted at enhancing awareness and developing self compassion—with elements from cognitive behavioural therapy.
MBCT is based on a theoretical premise similar to that on which cognitive behavioural therapy is based, and it uses strategies from that
therapy too. However, MBCT helps people to learn that the negative thoughts that can signal the start of a depressive episode are fleeting
events in the mind that they can choose to engage with or not. Through the mindfulness course people learn new ways of responding that
are more self compassionate, nourishing, and constructive. This is especially helpful at times of potential depressive relapse, when patients
learn to recognise habitual ways of thinking and behaving that tend to increase the likelihood of relapse and can choose instead to respond
adaptively.
Methods
We identified relevant studies and ongoing trials by searching Embase, PubMed, PsycINFO, Web of Science, Scopus, and the Cochrane
Central Register of Controlled Trials using the keywords “mindfulness-based cognitive therapy” or “MBCT” and “depress*”.
Is ongoing research likely to provide
relevant evidence?
Many of the uncertainties are answerable through well designed
and adequately powered studies (see “Recommendations” box);
indeed, in many cases this research is under way. Three ongoing
randomised controlled trials—in the UK,9 the Netherlands,10
and Australia11—ask how MBCT compares with, or can
augment, antidepressants in terms of preventing depressive
relapse. All three trials recruit from the population of adult
patients with a history of three or more episodes of depression
who are currently in remission, and all the trials report time to
depressive relapse as their primary outcome. The UK’s
PREVENT trial comparesMBCT plus tapering or discontinuing
maintenance antidepressants with maintenance antidepressants
alone in terms of preventing depressive relapse or recurrence
over 24 months.9 The Netherlands MOMENT study comprises
two parallel trials: the first trial compares maintenance
antidepressants with MBCT plus maintenance antidepressants;
the second compares MBCT plus tapering of maintenance
antidepressants withMBCT plus maintenance antidepressants.10
The primary outcome is relapse or recurrence over 15 months.
The Australian DARE trial is a single blind trial using group
comparison between MBCT and self monitoring (“depression
relapse active monitoring”); relapse over 24 months is the
outcome measure.11
However, these randomised controlled trials are not comparing
MBCT directly with other psychosocial interventions. A further
trial will compare MBCT with cognitive psychoeducation, an
equally plausible cognitive treatment delivered by the same
therapists and which does not require participants to practise
meditation.12
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Recommendations for further research
• Among patients at high risk for depressive relapse, how does MBCT compare with maintenance antidepressants alone or both
treatments together in preventing relapse? Can MBCT provide an alternative for people wishing to discontinue antidepressants?
• Among patients at high risk of depressive relapse, how does MBCT compare with other psychosocial approaches (such as cognitive
behavioural and interpersonal therapies) in preventing relapse?
• How acceptable is MBCT to a broad range of patients (for example, patients with different sociodemographic and cultural backgrounds
and patients with varied psychiatric and medical comorbidities)? Can the early indications that MBCT is effective only for patients with
three of more previous episodes be replicated?
• What are the facilitators and barriers to implementation of NICE’s recommendations for MBCT in the UK’s health services? Can this
knowledge be used to develop an implementation plan for introducing MBCT consistently into NHS service delivery?
What should we do in the light of the uncertainty? Practical advice on referring patients for MBCT and on
commissioning such services in the UK*
How do I know when to refer someone for cognitive behavioural therapy, interpersonal therapy, or mindfulness based
cognitive therapy?
All three psychosocial treatments are recommended by NICE, but cognitive behavioural and interpersonal therapies aim to help patients
with current depression get well and stay well. MBCT might therefore be considered for people who are well but still at substantial risk of
relapse—that is, those who have experienced three or more previous episodes of depression. This includes people who have relapsed
despite antidepressant treatment; who cannot or choose not to continue antidepressant treatment; and/or who have residual symptoms.
Such patients may present asking for long term support in the management of their depression or feel at risk of having future relapses after
drug or psychological treatment.
MBCT is best suited to people interested in a psychosocial approach to preventing future episodes of depression who are open and willing
to learn new ways of thinking and behaving and to learn within a group based context, and who can invest the time both to attend the groups
and to do the home practice.
What can referrers and patients expect from a MBCT service?
• MBCT is a group based class (8-15 participants). It involves eight weekly classes, each lasting two hours, facilitated by a teacher who
meets the UK’s Good Practice Guidelines for Teaching Mindfulness-based Courses (http://mindfulnessteachersuk.org.uk/).
• MBCT therapists would normally meet patients individually, before the classes start, to assess suitability for MBCT and to provide the
opportunity to explain more about the course and provide practical details.
• During the course, patients are asked to engage in about an hour a day of home practice to support their learning, supported by
audio-recorded, guided meditation practice sessions.
• After the course many services offer booster or reunion sessions, typically monthly or quarterly.
Commissioning depression services
To manage the typically recurrent course of depression, services should offer—as part of the care pathway for depression—MBCT to help
people to stay well
*Based on the current NICE guidelines13
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